Active, not recruitingPhase 3NCT03710876
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ferring Ventures Limited
- Principal Investigator
- Daniel Sterman, MDNYU Langone Laura and Isaac Perlmutter Cancer Center
- Intervention
- rAd-IFN(biological)
- Enrollment
- 53 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (29)
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
- University of California, San Francisco (UCSF), San Francisco, California, United States
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- Marlene & Stewart Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
- Monash Medical Centre, Clayton, Victoria, Australia
- Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Québec, Sainte-Foy, Canada
- Institut Bergonie, Bordeaux, France
- CHRU de Brest - Hopital Augustin Morvan, Brest, France
- CHU de Caen - Hopital Cote de Nacre, Caen, France
- CHRU de Lille, Lille, France
- Institut Curie - Oncologie Medicale, Paris, France
- +14 more locations on ClinicalTrials.gov
Collaborators
University of Pennsylvania
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03710876 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited